Showing 2771-2780 of 3244 results for "".
- Cetaphil® Marks Fifth Year of Support for CSDF and Camp Wonderhttps://practicaldermatology.com/news/cetaphil-marks-fifth-year-of-support-for-csdf-and-camp-wonder/2458452/Galderma Laboratories, L.P., makers of Cetaphil, is celebrating the fifth consecutive year of its "Meaningphil™" partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder.</
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- Study: Some Black Teens Pulled Between Health and Hairhttps://practicaldermatology.com/news/study-some-black-teens-pulled-between-health-and-hair/2458468/Some girls and women in the black community feel as if they have to choose between their health and their hair, and this may play a role in the high rates of obesity seen in this population, new research shows. Susan Woolford, M.D., MPH, , a pediatrician at the University
- Valeant Dermatology ASPIRE HIGHER Scholarship Program Names Winnershttps://practicaldermatology.com/news/valeant-dermatology-aspire-higher-scholarship-program-names-winners/2458472/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, announced the winners of its ASPIRE HIGHER Scholarship Program. Nine undergraduate and graduate students were selected from a pool of 970 applicants and awarded up to $10,000 each tow
- Indoor Tanning Rates Among Minors in NJ Stays Same Despite 2013 Banhttps://practicaldermatology.com/news/indoor-tanning-rates-among-minors-in-nj-stays-same-despite-2013-ban/2458494/Indoor tanning rates among children under age 17 in New Jersey didn’t budge after a ban enacted in 2013, and rates increased among male high school students in the Garden State from 2012 to 2014, according to a study in the Journal
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- Topix Pharmaceuticals Partners with New Mountain Capitalhttps://practicaldermatology.com/news/new-mountain-capital-partners-with-topix-pharmaceuticals/2458505/Topix Pharmaceuticals, Inc. has partnered with New Mountain Capital, LLC, a growth-oriented investment firm that currently manages over $15 billion in assets. New Mountain, a New York-based private equity firm, identified Topix through a proactive focus in the life sciences and aestheti
- Allergan Receives Positive Opinion Through European Decentralised Procedure For BELKYRA® (Deoxycholic Acid) For Submental Fullnesshttps://practicaldermatology.com/news/allergan-receives-positive-opinion-through-european-decentralised-procedure-for-belkyra-deoxycholic-acid-for-submental-fullness/2458511/The Swedish Medical Products Agency (MPA) gave its thumbs up to Allergan’s BELKYRA® (deoxycholic acid). BELKYRA® is being